In summary, the lupus nephritis therapeutic effect of PLYCSB was evaluated by various in vivo experimental methods, including serum cytokine assays of IL-6, IL-12, TNF-α and IFN-γ; an assay for serum levels of SCr, BUN, TC, TG, TP and ALB; an auto-antibody ds-DNA assay, analysis of urinary protein excretion, a histology assay, tissue RT-PCR and western blot assays for checking the inflammatory related genes of NF-κB-p65, IκB-α, TGF‐β1, Fas and FasL. The gene discussed is NFKBIA; the disease is lupus nephritis.